Evidence map›Paper›PMID 37743383›Full record

ArticleScientific reports2023

Serum APOC1 levels are decreased in young autoantibody positive children who rapidly progress to type 1 diabetes.

M Karoliina Hirvonen, Niina Lietzén, Robert Moulder, Santosh D Bhosale, Jaakko Koskenniemi, Mari Vähä-Mäkilä, Mirja Nurmio, Matej Orešič, Jorma Ilonen, Jorma Toppari and 6 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

M Karoliina HirvonenTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Niina LietzénTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Robert MoulderTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.ORCID http://orcid.org/0000-0003-4742-0566
Santosh D BhosaleTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Jaakko KoskenniemiInFLAMES Research Flagship Center, University of Turku, Turku, Finland.
Mari Vähä-MäkiläDepartment of Pediatrics, University of Turku and Turku University Hospital, Turku, Finland.
Mirja NurmioDepartment of Pediatrics, University of Turku and Turku University Hospital, Turku, Finland.
Matej OrešičTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.ORCID http://orcid.org/0000-0002-2856-9165
Jorma IlonenImmunogenetics Laboratory, University of Turku, Turku, Finland.
Jorma ToppariInFLAMES Research Flagship Center, University of Turku, Turku, Finland.
Riitta VeijolaDepartment of Pediatrics, Research Unit of Clinical Medicine, Medical Research Center, University of Oulu, Oulu, Finland.ORCID http://orcid.org/0000-0002-6557-270X
Heikki HyötyFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Harri LähdesmäkiDepartment of Computer Science, Aalto University School of Science, Aalto, Finland.
Mikael KnipPediatric Research Center, New Children's Hospital, Helsinki University Hospital, Helsinki, Finland.ORCID http://orcid.org/0000-0003-0474-0033
Lu ChengDepartment of Computer Science, Aalto University School of Science, Aalto, Finland. lu.cheng@aalto.fi.
Riitta LahesmaaTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland. rilahes@utu.fi.
Åbo Akademi University · FIUniversity of Turku · FIAalto University · FIOulu University Hospital · FITampere University · FIUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Better understanding of the early events in the development of type 1 diabetes is needed to improve prediction and monitoring of the disease progression during the substantially heterogeneous presymptomatic period of the beta cell damaging process. To address this concern, we used mass spectrometry-based proteomics to analyse longitudinal pre-onset plasma sample series from children positive for multiple islet autoantibodies who had rapidly progressed to type 1 diabetes before 4 years of age (n = 10) and compared these with similar measurements from matched children who were either positive for a single autoantibody (n = 10) or autoantibody negative (n = 10). Following statistical analysis of the longitudinal data, targeted serum proteomics was used to verify 11 proteins putatively associated with the disease development in a similar yet independent and larger cohort of children who progressed to the disease within 5 years of age (n = 31) and matched autoantibody negative children (n = 31). These data reiterated extensive age-related trends for protein levels in young children. Further, these analyses demonstrated that the serum levels of two peptides unique for apolipoprotein C1 (APOC1) were decreased after the appearance of the first islet autoantibody and remained relatively less abundant in children who progressed to type 1 diabetes, in comparison to autoantibody negative children.

Indexed as

Diabetes Mellitus, Type 1Insulin-Secreting CellsApolipoprotein C-IAutoantibodiesChildChild, PreschoolDisease ProgressionHumansApolipoprotein C-IAutoantibodies

Identifiers

PMID37743383
PMCPMC10518308
OpenAlexW4386998331

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.